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Simulation of Acute Myopericarditis by Constrictive Pericardial
Disease With Endomyocardial Fibrosis Due to Methysergide Therapy
A. DANIEL HARBIN, MD,* MYRON C. GERSON, MD, FACC,*t JOHN B. O'CONNELL, MD, FACe!:
Cincinnati, Ohio and Maywood, Illinois
Methysergide (Sansert) has been associated with nu-
merous fibrotic disorders. In particular, multiple car-
diac lesions have been described in cases where methy-
sergide was thought to have played a causative role. A
patient is described who presented with cardiac findings
suggestive of acute myopericarditis. An inflammatory
myocarditis was subsequently excluded by endomyocar-
Methysergide (Sansert) is an analog and antagonist of se-
rotonin that has been used widely during more than two
decades for the prophylaxis of migraine or cluster head-
aches. Although methysergide may be the most effective
agent available for prophylaxis against certain types of dis-
abling headaches, its use has been marred by adverse effects
in some patients. A small percent of patients using methy-
sergide develop fibrotic disorders that may become life-
threatening. Retroperitoneal fibrosis was initially recognized
in 1961 (1), but methysergide-associated fibrotic processes
in the cardiovascular system have included valvular fibrosis
leading to aortic, mitral or tricuspid regurgitation (1-10),
constrictive pericardial disease (11-13), cotonary artery dis-
ease (1,3,5,14) and myocardial fibrosis (5,6,15). We report
on a patient whose initial presentation mimicked acute viral
myopericarditis, but who was later shown to have evidence
of both endomyocardial fibrosis and pericardial disease as
complications of methysergide therapy.
Case Report
Initial presentation. A 61 year old white male executive
was in excellent health until December 1982, when he noted
the onset of fatigue, night sweats, anorexia and occasional
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dial biopsy. Hemodynamic findings suggested the pres-
ence of constrictive pericarditis or restrictive cardio-
myopathy, or both. Radiographic evidence of constrictive
pericarditis and biopsy evidence of endocardial fibrosis
were documented in this patient with a long history of
interrupted methysergide therapy.
chest pains. One month later while attending a business
convention in the Virgin Islands, he required hospitalization
for increasing chest pain accompanied by exertional dyspnea
and pedal edema. In the hospital a pericardial friction rub
was heard, and pedal edema, pulmonary rales and hepa-
tomegaly were noted. Acute myocardial infarction was ex-
cluded by serial measurement of cardiac serum enzymes and
serial electrocardiograms. After symptomatic improvement
with digoxin and diuretic drug therapy (furosemide), the
patient returned home.
Later evaluation. On the day of his return home, the
patient presented for the first time to the University of Cin-
cinnati Medical Center and was admitted for further eval-
uation. On examination, bilateral rales, pedal edema and a
pericardial friction rub were present. There was no abnormal
jugular venous distension or cardiac gallop rhythm. The oral
body temperature was 100°F (37.7°C). There was a history
of renal calculi, and a past intravenous pyelogram suggested
minor deviation in the course of the right ureter. Results of
a treadmill exercise test performed I year earlier as part of
an executive physical examination were normal. The only
medication at the time of admission was methysergide, 2
mg twice daily, which the patient had taken for prophylaxis
of vascular headaches for 10 years. The methysergide had
been discontinued for a 2 week period every 6 months.
There was roentgenographic evidence of bilateral pleural
effusion with an enlarged cardiac silhouette. The electro-
cardiogram revealed persistently inverted T waves in leads
II, III and aVF, in association with intermittently inverted
T waves in all precordial leads. There was echocardio-
graphic evidence of pericardial effusion and mild left atrial
dilation (5.0 ern) without evidence of other abnormalities.
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Figure I. Photomicrographs of endomyocardial biopsy specimen .
Hematoxylin-eosin stain at 4 x original magnification (left), and
elastic tissue stain at 10x original magnification (right). The
endocard ium (E) demonstrates fibrosis and thickening , while the
myocardium (M) is normal. The white arrow shows elastic tissue.
A radionuclide-determined left ventricular ejection fraction
was OA8 with generalized mild left ventricular hypokinesia.
The erythrocyte sedimentation rate was 82 mm in I hour.
Antinuclear, antimitochondrial , antismooth muscle, anti-
parietal cell and antithyroid antibodies were absent. The
third component of complement C3 was slightly elevated at
220 (normal 83 to 177) with a normal C4 and total hemolytic
complement (CH lOo) . Double and single-stranded deoxyri-
bonucleic acid (DNA) binding, antiDNAase-B and anti-
streptolysin 0 were normal. Serologic titers for Histoplasma
capsulatum and Coxsackie B virus were less than 1:8 di-
lutions. An indium-Ill white blood cell scan was negative
for evidence of myocardial inflammation.
Methysergide therapy was discontinued on admission .
After I week the patient was discharged receiving no med-
ication except for aspirin, which controlled his headaches .
One week later , a repeat blood pool radionuclide scan dem-
onstrated a decrease in the left ventricular ejection fraction
to 0.40.
Clinical deterioration. Within I week after hospital dis-
charge , exertional dyspnea and pedal edema returned and
furosemide therapy was resumed . A repeat left ventricular
ejection fraction determination I week later demonstrated a
further decrease to 0.33. With the documentation of pro-
gression in left ventricular dysfunction in the setting of a
recent illness suggestive of a viral infection , the patient was
referred to Loyola University Medical Center for endo-
myocardial biopsy with a presumptive diagnosis of acute
myopericarditis.
At the time ofendomyocardial biopsy , hemodynamic de-
terminations were found to be supportive of constrictive or
restrictive physiology. Blood pressure values (nun Hg) were:
Figure 2. Computed tomogram of the chest demon-
strates marked pericardial thickening (white arrows) .
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Figure 3. Simultaneous recording of left
ventricular (LV) and right ventricular (RV)
pressures. Diastolic pressure equalization in
these chambers is demonstrated, in addition
to the dip-plateau pattern characteristic of re-
strictive or constrictive hemodynamics.
mean right atrial 15, right ventricular end-diastolic 18, pul-
monary artery 28/18 , mean pulmonary capillary wedge 17,
and left ventricular end-diastolic 18. After intravenous in-
fusion of 500 cc of normal saline solution over a 20 minute
period , the right atrial pressure was 17 and the pulmonary
capillary wedge pressure was 19.
Six endomyocardial biopsy specimens were obtained from
the right ventricle and demon strated marked endocardial
fibrosis (Fig. 1) . Minimal elastosis was seen with elastic
tissue staining. No histologic evidence for myocardial in-
flammation was found . Myocardial cultures were negative
for virus. Computed tomograph y of the chest was performed
and a markedly thickened pericardium (maximal width 0 .55
ern) was documented (Fig. 2). A gallium-76 scan of the
heart was negative for evidence of myocardial inflammation .
Repeat hemodynamic evaluation. While the patient was
not receiving methysergide , his headaches remained mild
and were easily controlled with aspirin. Two months after
his initial hospitalization , he began to note progressive ex-
ertional chest pain . Coronary angiography demonstrated
normal coronary arteries . Repeat hemodynamic determi-
nations suggested possible improvement in the previously
observed constrictive/restricti ve hemodynamics (Fig. 3).
Pressures (mm Hg) were as follows: mean right atrial 10,
right ventricular 24/12 , pulmonary artery 24/12; pulmonary
capillary wedge 12 and left ventricular end-diastolic 12.
Figure 4. Computed tomogram of the
chest obtained 5 months after discon-
tinuation of methysergide. In compar-
ison with the earlier study (Fig. 2),
decreased pericardial thickness is
demonstrated.
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Thermodilution cardiac output was 4.54 liters/min. After
intravenous infusion of 500 cc of normal saline solution
over 20 minutes, the mean right atrial pressure increased to
II , right ventricular end-diastolic pressure to 15, pulmonary
artery diastolic pressure to 14 and left ventricular end-dia-
stolic pressure to 15.
Subsequent clinical course. Currentl y, the patient has
returned to full employment without cardiac symptoms on
diuretic drug therapy (furosemide, 40 mg daily). He has
been advised not to resume methysergide use. A follow-up ,
radionuclide ventriculogram at rest demonstrated an increase
in the left ventricular ejection fraction to 0.44. Computed
tomography of the chest repeated 5 months after discon-
tinuation of methysergide demonstrated a decrease in the
pericardial thickness, with a maximal width of 0.30 em
(Fig. 4) .
Discussion
Previous reports. Fibrotic disorders in association with
methysergide therapy have long been recognized . Patho-
logic demonstration of the fibrotic cardiac process was re-
ported in 1966 (I ). A 36 year old woman recei ving long-
term methysergide therapy developed significant aortic in-
sufficiency and sustained a myocardial infarction. After aor-
tic valve replacement, the excised tissue demonstrated a
thickened and fibrotic ring involving the root of the aorta
and the left coronary artery orifice, with fibrosis lining the
aortic valve leaflets (l,3). Subsequent histopathologic stud-
ies (3,5,9) have confirmed that in methysergide-related car-
diac involvement, as in the carcinoid syndrome, the cardiac
valve structure itself is not significantly affected. There is
an orderly deposition of overlying fibrous tissue on the car-
diac valve.
In addition to cardiac valvular lesions, pericardial in-
volvement (I 1-13), including a case with constrictive hemo-
dynamics (13), has been documented. A difference between
our pat lent and the patient described by Orlando et al. (13)
is that our patient was complying with a regimen of inter-
rupted methysergide therapy. Furthermore, our patient dem-
onstrated radiographic evidence of regression of pericardial
thicken ing along with some objective hemodynamic evi-
dence of improvement on discontinuation of methysergide ,
whereas the patient of Orlando et al. required pericardiectomy.
Myocardialfibrosis in association with methysergide use
has also been documented by right ventricular endomyo-
cardial biopsy (6) and autops y (15). The patient of Mason
et a!. (til represents the only other reported case of cardiac
compli cations in association with appropriately interrupted
rnethysergide therapy. No suggestion of pericardial disease
was reported in the patient of Mason et al. (6).
Myopericarditis simulation. Our patient represents a
unique and interesting case because his initial clinical pre-
sentation was suggestive of an acute viral myopericarditis .
Endomyocardial biopsy was helpful in excluding an inflam-
matory myocardial process and confirming the presence of
endom yocardial fibrosis apparently related to chronic inter-
rupted methysergide therap y. The computed tomograms of
the chest demonstrated pericardial thickening. In association
with the hemodynamic abnormalities described, the findings
support a diagnosis of constrictive pericardial disease , al-
though restrictive physiology is not excluded. Both peri-
cardial and endomyocardial fibrosis were documented-two
known compl ications of methysergide therapy that have not
previously been reported in the same patient.
Implications. Patients using methysergide, even on an
interrupted program, should be closely observed by their
physicians for signs of cardiac disease. A patient with chronic
complications of methysergide therapy , such as pericardial
and endomyocardial fibrosis, can have an initial clinical
presentation that may mimic unrelated acute disease and
otherwise delay correct diagnosis.
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